First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

AstraZeneca has upped its revenue expectations ... The company’s cancer immunotherapy Imfinzi (durvalumab) is also shaping up to become a billion dollar a year drug as countries outside the ...

AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293. The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 20,473.75 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder cancer, a significant advancement in cancer therapy. The approval allows ...